Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.

Ayman Al-HendyAndrea S LukesAlfred N PoindexterRoberta VenturellaClaudio VillarroelHilary O D CritchleyYulan LiLaura McKainJuan C Arjona FerreiraAndria G M LangenbergRachel B WagmanElizabeth A Stewart

Published in: The New England journal of medicine (2021)

Once-daily relugolix combination therapy resulted in a significant reduction in menstrual bleeding, as compared with placebo, and preserved bone mineral density in women with uterine fibroids. (Funded by Myovant Sciences; LIBERTY 1 [L1] and LIBERTY 2 [L2] ClinicalTrials.gov numbers, NCT03049735 and NCT03103087, respectively.).

Keyphrases

combination therapy
bone mineral density
postmenopausal women
body composition
atrial fibrillation
physical activity
pregnant women
randomized controlled trial
sleep quality
replacement therapy